Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2020-02-26 Remuneration Information
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2019
Remuneration Information Classification · 99% confidence The document text explicitly discusses the 'POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD' (Remuneration Policy of the Company) for directors ('consejeros') for the period 2019-2021. It details the structure, principles, fixed vs. variable components, and risk mitigation measures related to executive and non-executive director compensation. This content directly aligns with the definition of Remuneration Information, which corresponds to the DEF 14A filing type in the US context, or equivalent detailed disclosure regarding executive pay, which is mapped to 'DEF 14A' in the provided schema definitions.
2020-02-26 Spanish
Corporate Governance Report - Pharma Mar S.A.
Remuneration Information Classification · 99% confidence The document text explicitly discusses the 'POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD' (Remuneration Policy of the Company) for directors ('consejeros') for the period 2019-2021. It details fixed vs. variable compensation, criteria for executive compensation (specifically the CEO), and risk mitigation measures related to pay. This content directly aligns with the definition of Remuneration Information, which corresponds to the DEF 14A filing type in the US context, or similar detailed governance reports on executive pay in other jurisdictions. Given the provided options, 'DEF 14A' (Proxy Solicitation & Information Statement, often containing remuneration details, or more accurately, the specific remuneration report section) is the closest fit, although 'CGR' (Governance Information) could also be considered. However, the focus is overwhelmingly on remuneration details, making DEF 14A the most specific match among the choices for detailed compensation reporting.
2020-02-26 Spanish
Pharma Mar informa que la FDA ha aceptado y concedido la revisión prioritaria a su solicitud de registro para la aprobación acelerada de lurbinectedina para tratamiento de cáncer de pulmón microcítico
Earnings Release Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) and is explicitly titled 'INFORMACIÓN PRIVILEGIADA' (Inside Information). It announces a significant regulatory event: the FDA accepting and granting priority review for a New Drug Application (NDA) for lurbinectedin. The text also mentions that a press release is attached ('Se adjunta nota de prensa'). This structure—a formal regulatory notification containing key updates and referencing an attached press release—is characteristic of a general regulatory announcement rather than a specific periodic report (like 10-K or IR) or the full press release itself. Since it is a mandatory disclosure to the regulator that doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), the most appropriate general category for significant, non-standard regulatory disclosures in this context is Regulatory Filings (RNS). The document length (8088 chars) is substantial, but its primary function is the regulatory notification itself. FY 2020
2020-02-17 Spanish
Annual Report 2018
Annual Report Classification · 100% confidence The document is titled 'Cuentas Anuales e Informe de Gestión al 31 de diciembre de 2018' (Annual Accounts and Management Report as of December 31, 2018) for Pharma Mar, S.A. It contains detailed financial statements, including the Balance Sheet and Profit and Loss Account, with comparative data for 2017 and 2018. This constitutes a comprehensive annual financial report, which falls under the 10-K category in the provided schema. FY 2018
2019-03-01 Spanish
Corporate Governance Report - Pharma Mar S.A.
Remuneration Information Classification · 99% confidence The document text is titled 'A. POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD PARA EL EJERCICIO EN CURSO' (Remuneration Policy of the Company for the Current Fiscal Year) and extensively details the remuneration policy for directors and executive directors, including fixed vs. variable components, alignment with shareholder interests, and risk mitigation measures related to compensation. This content directly corresponds to the definition of Remuneration Information, which maps to the filing code DEF 14A (Proxy Solicitation & Information Statement, often containing executive compensation details, or specifically remuneration reports in some jurisdictions). Although the document discusses the policy for the 2019-2021 period, it is providing the current information regarding remuneration as required, and the structure strongly suggests a disclosure related to executive compensation, which is the core function of DEF 14A (or similar remuneration reports). Given the specific focus on 'Política de Remuneraciones' (Remuneration Policy) and the detailed breakdown of director/executive pay structures, DEF 14A is the most appropriate classification among the provided options, as it covers compensation details often found in proxy statements.
2019-02-28 Spanish
Pelican House Mining Plc - Outcome of General Meeting
AGM Information Classification · 99% confidence The document explicitly states it is the "Outcome of General Meeting" and details the results of resolutions passed, including a name change and the effect on a conditional share placing. This directly corresponds to the purpose of reporting the results of a shareholder vote, which aligns with the Declaration of Voting Results & Voting Rights Announcements (DVA). Although it mentions the AGM notice date, the core content is the outcome announcement.
2019-01-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.